Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

FSD Pharma Inc. (C:HUGE)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Mostly sunny as of January 01, 2023
For the latest outlook, get the company report

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for HUGE within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 19, 2023 06:00 ET
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial...
Read full article
Jan 17, 2023 08:30 ET
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission of the Company’s Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of Multiple Sclerosis (MS).
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.02
--
--
Price to Sales - TTM
--
3.81
4.89
Price to Book - most recent quarter
1.02
1.78
1.79
Price to Cash Flow per share - TTM
--
3.58
9.87
Price to Free Cash Flow per share - TTM
--
4.22
12.79
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 15, 202339,86722,200
Dec 31, 202217,66711,141
Dec 15, 20226,5263,378
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

FSD Pharma Inc. is a Canada-based biotechnology company. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its compound, ultra-micronized palmitoyl ethylamine (PEA). The Company, through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), is also focused on the research and development of its lead compounds, Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. The Company's wholly owned subsidiaries include Prismic Pharmaceuticals Inc. and FV Pharma Inc.

See business summary

 

Twitter

Search (past week) for $HUGE.CA

  • No tweets found